IE37481L - 3-formylrifamycin azines - Google Patents
3-formylrifamycin azinesInfo
- Publication number
- IE37481L IE37481L IE730508A IE50873A IE37481L IE 37481 L IE37481 L IE 37481L IE 730508 A IE730508 A IE 730508A IE 50873 A IE50873 A IE 50873A IE 37481 L IE37481 L IE 37481L
- Authority
- IE
- Ireland
- Prior art keywords
- rifamycin
- derivatives
- formylrifamycin
- aliphatic
- divalent
- Prior art date
Links
- BBNQHOMJRFAQBN-UPZFVJMDSA-N 3-formylrifamycin sv Chemical compound OC1=C(C(O)=C2C)C3=C(O)C(C=O)=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BBNQHOMJRFAQBN-UPZFVJMDSA-N 0.000 title abstract 3
- 125000001931 aliphatic group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- -1 cycloaliphatic Chemical group 0.000 abstract 3
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 229930189077 Rifamycin Natural products 0.000 abstract 1
- HJYYPODYNSCCOU-ZDHWWVNNSA-N Rifamycin SV Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(O)c4c3C2=O HJYYPODYNSCCOU-ZDHWWVNNSA-N 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 abstract 1
- 229960003292 rifamycin Drugs 0.000 abstract 1
- 229940109171 rifamycin sv Drugs 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1392272 Rifamycin derivatives GRUPPO LEPETIT SpA 29 March 1973 [31 May 1972] 15l91/ Heading C2C Derivatives of rifamycin SV having the general formula and 16, 17, 18, 19, 28 and 29 hexahydro and 25-desacetyl derivatives thereof wherein the symbol Rifa represents the rifamycin radical of formula and A represents (1) a direct bond connecting the two nitrogen atoms ; (2) a group wherein y is -CO-, -CNH-, -CS-, -SO 2 -, a divalent, aliphatic, cycloaliphatic, aromatic, araliphatic, or heterocyclic radical; R 2 and R 3 indedendently represent hydrogen, alkyl or taken together represent an aliphatic divalent chain of 1-4 carbon atoms connecting the two terminal nitrogen atoms, or (3) a divalent group wherein X represents a direct bond between the two carbon atoms, a divalent aliphatic, cycloaliphatic, aromatic, or heterocyclic radical, R and R 1 may be independently hydrogen, alkyl, cycloalkyl, aryl, heterocyclic or taken together represent an aliphatic chain of 1 to 8 C atoms connecting the two terminal carbon atoms, may be prepared by reacting 3-formylrifamycin SV or its 25-desacetyl or 16, 17, 18, 19, 28 and 29 hexahydro derivative with a hydrazine compound of the formula H 2 N-A-NH 2 in an inert organic solvent at a temperature ranging from room temperature to the boiling temperature of the solvent. Compounds prepared include 3-formylrifamycin SV azine, 16, 17, 18, 19, 28, 29 - hexahydro - 3 - formylrifamycin SV azine and 1,4-piperazinylidene-bis-(3,3<SP>1</SP>-iminomethyl rifamycin SV). Pharmaceutical compositions having antibacterial and anti-tumour activity comprise the above derivatives of rifamycin SV and a pharmaceutically acceptable carrier.
[GB1392272A]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2507572 | 1972-05-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE37481L true IE37481L (en) | 1973-11-30 |
| IE37481B1 IE37481B1 (en) | 1977-08-03 |
Family
ID=11215624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE508/73A IE37481B1 (en) | 1972-05-31 | 1973-03-30 | 3-formylrifamycin azines |
Country Status (21)
| Country | Link |
|---|---|
| JP (1) | JPS516679B2 (en) |
| AR (2) | AR198663A1 (en) |
| AT (1) | AT323885B (en) |
| BE (1) | BE800276A (en) |
| CA (1) | CA992961A (en) |
| CH (1) | CH573433A5 (en) |
| DD (1) | DD107285A5 (en) |
| DE (1) | DE2326698A1 (en) |
| ES (1) | ES414894A1 (en) |
| FR (1) | FR2186231B1 (en) |
| GB (1) | GB1392272A (en) |
| HU (1) | HU167317B (en) |
| IE (1) | IE37481B1 (en) |
| IL (1) | IL41926A (en) |
| LU (1) | LU67695A1 (en) |
| NL (1) | NL154510B (en) |
| PL (1) | PL87112B1 (en) |
| RO (1) | RO65182A (en) |
| SE (1) | SE386444B (en) |
| SU (1) | SU514572A3 (en) |
| ZA (1) | ZA732293B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1478563A (en) * | 1975-03-05 | 1977-07-06 | Lepetit Spa | Rifamycin derivatives |
-
1973
- 1973-03-29 GB GB1519173A patent/GB1392272A/en not_active Expired
- 1973-03-30 IE IE508/73A patent/IE37481B1/en unknown
- 1973-04-02 IL IL41926A patent/IL41926A/en unknown
- 1973-04-03 ZA ZA732293A patent/ZA732293B/en unknown
- 1973-05-08 AR AR247892A patent/AR198663A1/en active
- 1973-05-11 CA CA171,060A patent/CA992961A/en not_active Expired
- 1973-05-18 ES ES414894A patent/ES414894A1/en not_active Expired
- 1973-05-25 DE DE2326698A patent/DE2326698A1/en active Pending
- 1973-05-25 NL NL737307319A patent/NL154510B/en not_active IP Right Cessation
- 1973-05-29 FR FR7319518A patent/FR2186231B1/fr not_active Expired
- 1973-05-29 SU SU1920394A patent/SU514572A3/en active
- 1973-05-29 LU LU67695A patent/LU67695A1/xx unknown
- 1973-05-29 DD DD171159A patent/DD107285A5/xx unknown
- 1973-05-29 AT AT468173A patent/AT323885B/en not_active IP Right Cessation
- 1973-05-29 SE SE7307611*A patent/SE386444B/en unknown
- 1973-05-29 JP JP48059434A patent/JPS516679B2/ja not_active Expired
- 1973-05-29 RO RO7374946A patent/RO65182A/en unknown
- 1973-05-30 CH CH783173A patent/CH573433A5/xx not_active IP Right Cessation
- 1973-05-30 PL PL1973162950A patent/PL87112B1/pl unknown
- 1973-05-30 BE BE131720A patent/BE800276A/en unknown
- 1973-05-30 HU HULE706A patent/HU167317B/hu unknown
- 1973-12-19 AR AR251497A patent/AR198715A1/en active
Also Published As
| Publication number | Publication date |
|---|---|
| HU167317B (en) | 1975-09-27 |
| CA992961A (en) | 1976-07-13 |
| CH573433A5 (en) | 1976-03-15 |
| IE37481B1 (en) | 1977-08-03 |
| LU67695A1 (en) | 1973-08-02 |
| IL41926A (en) | 1976-04-30 |
| SU514572A3 (en) | 1976-05-15 |
| SE386444B (en) | 1976-08-09 |
| JPS516679B2 (en) | 1976-03-01 |
| JPS4942698A (en) | 1974-04-22 |
| ES414894A1 (en) | 1976-02-01 |
| ZA732293B (en) | 1974-02-27 |
| PL87112B1 (en) | 1976-06-30 |
| AU5616173A (en) | 1974-11-28 |
| AR198715A1 (en) | 1974-07-15 |
| IL41926A0 (en) | 1973-06-29 |
| FR2186231B1 (en) | 1976-03-05 |
| NL154510B (en) | 1977-09-15 |
| DD107285A5 (en) | 1974-07-20 |
| DE2326698A1 (en) | 1973-12-13 |
| BE800276A (en) | 1973-09-17 |
| FR2186231A1 (en) | 1974-01-11 |
| GB1392272A (en) | 1975-04-30 |
| NL7307319A (en) | 1973-12-04 |
| AT323885B (en) | 1975-08-11 |
| AR198663A1 (en) | 1974-07-15 |
| RO65182A (en) | 1981-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2083534A1 (en) | Indolopyrrolocarbazole derivatives | |
| WO2001023375A3 (en) | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | |
| MY113208A (en) | Pharmaceutical and compositions inhibiting kinases | |
| IE781878L (en) | Imidazole derivatives | |
| IE42881L (en) | Rifamycin compound | |
| ES463803A1 (en) | O-[3-(4-Substituted-piperazin-1-yl)-2-hydroxypropyl]-hydroxylamines | |
| IE36221L (en) | Cephalosporins | |
| IE37481B1 (en) | 3-formylrifamycin azines | |
| ES380221A1 (en) | S-triazine derivatives | |
| GB1219360A (en) | Improvements in or relating to the preparation of rifamycins | |
| GB1194598A (en) | Benzofuran Derivatives | |
| IE44373L (en) | Pyridthione derivatives | |
| GB1316689A (en) | Trifamycin derivatives | |
| IE36443L (en) | 3-formylrifamycin sv derivatives | |
| GB1366283A (en) | 3-hydrazonomethyl rifamycin sv | |
| EP0618204A4 (en) | Heterocyclic compound and cardiotonic containing the same as active ingredient. | |
| EP0034002A3 (en) | Carboxamidine derivatives | |
| IE36278B1 (en) | Pharmaceutical compositions containing benzofuran derivatives | |
| IE38562L (en) | 3-alkenyl derivatives of rifamycin sv | |
| AU624724B2 (en) | Pyrrolo(2,1-b)thiazole derivatives | |
| ES281455A1 (en) | 2-(5-nitro-2-furyl)-imidazo [1, 2-alpha]-pyridine or-pyrimidine | |
| GB1283187A (en) | Improvements in or relating to rifamycin derivatives and the preparation thereof | |
| ES427763A1 (en) | Disperse dyestuffs | |
| GB1289189A (en) | ||
| GB1445287A (en) | Derivatives of iboga type alkaloids |